Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites

Overview

The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites and the correction of hyponatraemia when used concomitantly with a standard dose regimen of spironolactone. The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites. This Hypo~CAT study is followed by a single-blind, placebo-controlled, one-year long-term safety extension (Expo~CAT). The first extension is followed by another long-term study (PASCCAL-1).

Full Title of Study: “SR121463B in Cirrhotic Ascites Treatment With Hyponatraemia: A Placebo-Controlled, Dose-Comparison Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: March 2005

Interventions

  • Drug: satavaptan (SR121463B)

Clinical Trial Outcome Measures

Primary Measures

  • change in body weight, change in serum sodium
    • Time Frame: within 14 days

Secondary Measures

  • abdominal girth and discomfort
    • Time Frame: 14 days
  • paracentesis
    • Time Frame: 14 days
  • trail-making test and quality of life
    • Time Frame: 14 days

Participating in This Clinical Trial

Inclusion Criteria

  • Cirrhosis of the liver confirmed by ultrasound, endoscopic examination, or biochemical evidence – Moderate or tense ascites – Patients with hyponatremia, defined as a serum sodium concentration of ≤130 mmol/L The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sanofi
  • Provider of Information About this Clinical Study
    • ICD Study Director, sanofi-aventis
  • Overall Official(s)
    • ICD CSD, Study Director, Sanofi

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.